Leadership Overview
Gland Pharma has 4 executives leading key functions including strategy, technology, finance, and regional operations.
Driven by a commitment to high-quality and affordable products, Gland Pharma meets diverse injectable needs across the pharmaceutical industry, leveraging robust R&D and manufacturing capabilities to supply global markets.
Driven by a commitment to high-quality and affordable products, Gland Pharma meets diverse injectable needs across the pharmaceutical industry, leveraging robust R&D and manufacturing capabilities to supply global markets.
Leadership Roles at Gland Pharma
Ravi Penmetsa - Managing Director & Chief Executive Officer
Ravi Penmetsa, the Managing Director & Chief Executive Officer at Gland Pharma, directs the company's overall strategic vision and operational execution. Overseeing global expansion and market penetration, Penmetsa ensures Gland Pharma's continued growth in supplying complex generic injectables to key markets like the United States, Europe, Canada, Australia, and India. This leadership role involves aligning research and development initiatives with manufacturing capabilities to produce high-quality, affordable pharmaceutical products. Ravi Penmetsa drives the business-to-business model, fostering strong relationships with partners worldwide and solidifying the company's position as a leading manufacturer. The Chief Executive Officer's focus remains on enhancing operational efficiency and expanding the product portfolio to address diverse injectable needs across the pharmaceutical sector, thereby securing Gland Pharma's long-term market leadership and financial stability.
Annie William - Regional Chief Executive Officer
Annie William, the Regional Chief Executive Officer at Gland Pharma, spearheads operations and market development within specific geographic territories. Overseeing regional business strategies, William ensures Gland Pharma effectively serves its diverse customer base across markets such as North America and Europe. This role involves driving sales performance, managing regional P&L, and fostering strong client relationships within the business-to-business framework. Annie William focuses on adapting global strategies to local market dynamics, ensuring compliance with regional regulations and optimizing supply chain logistics for timely product delivery. The Regional Chief Executive Officer's leadership is vital for expanding Gland Pharma's footprint and reinforcing its reputation for delivering high-quality, affordable generic injectables. William's operational oversight directly contributes to the company's sustained international growth and market penetration.
Ravi Mitra - Chief Financial Officer
Ravi Mitra, the Chief Financial Officer at Gland Pharma, manages the company's financial strategy and fiscal health. Overseeing all financial operations, Mitra ensures robust capital allocation, risk management, and profitability across Gland Pharma's global markets, including the United States, Europe, Canada, Australia, and India. This leadership position involves driving financial planning, budgeting, and reporting to support the company's rapid growth and expansion initiatives. Ravi Mitra plays a key role in securing funding, optimizing investment strategies, and maintaining strong relationships with financial institutions and stakeholders. The Chief Financial Officer's expertise is crucial for sustaining the business-to-business model and ensuring the financial viability of producing high-quality, affordable generic injectables. Mitra's financial stewardship underpins Gland Pharma's capacity to invest in R&D and manufacturing excellence.
K.V.G.K. Raju - Chief Technology Officer
K.V.G.K. Raju, the Chief Technology Officer at Gland Pharma, architects the company's technological infrastructure and innovation pipeline. Overseeing research and development efforts, Raju ensures Gland Pharma maintains its edge in complex injectables, oncology, and ophthalmics. This critical function involves integrating advanced manufacturing technologies and optimizing production processes to meet stringent global quality standards. K.V.G.K. Raju drives the adoption of cutting-edge scientific methodologies, directly supporting the development of new generic injectable formulations. The Chief Technology Officer's responsibilities extend to enhancing the company's R&D capabilities, ensuring seamless technology transfer from lab to large-scale manufacturing, and maintaining compliance with international regulatory requirements across all operational geographies. Raju's leadership ensures Gland Pharma's technological prowess underpins its global supply chain effectiveness.
Explore Leadership Teams in Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ST
ES
Sumitomo Pharma seeks to continuously create innovative pharmaceutical products by pursuing R&D activities focused on Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, all the while incorporating cutting-edge technologies. We also seek to contribute to Global Health through our work in the area of Infectious Disease, and furthermore, through our Frontier Business, we are pursuing R&D and commercialization of new healthcare solutions other than pharmaceuticals for addressing social issues which cannot be solved by pharmaceuticals alone.
Company Leadership TS
JS
JH
RG
Founded in 1995, The Ritedose Corporation is a manufacturing and packaging facility, located in Columbia, SC.
Company Leadership
DM
JM
Kite Pharma, founded in 2009, is a pharmaceutical company specializing in cell therapy to treat and potentially cure cancer. The company focuses on engineered T cell therapy for hematologic malignancies and is committed to making these innovative treatments accessible to eligible patients. Unlike traditional pharmaceutical manufacturing, Kite Pharma's approach involves reengineering a patient's own immune cells to fight cancer cells individually. The company operates dedicated cell therapy manufacturing facilities in California, Maryland, and the Netherlands, with corporate headquarters in Santa Monica, California. Kite Pharma continues to advance cancer immunotherapy through its specialized treatments and research.
Company Leadership NS
LM
KD
Frequently Asked Questions Regarding Gland Pharma Top Executives and Leadership Team
